MedTrace Logo

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 564

Last updated 2021-06-07

Study results available
· View outcomes & findings →

Summary

This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Aliskiren

300 mg tablet

DRUG

Amlodipine

5 mg tablet

DRUG

Hydrochlorothiazide

12.5 mg and 25 mg capsule

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-05
Primary Completion
2009-10-05
Completion
2009-10-05
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Egypt
  • Germany
  • Poland
  • Slovakia
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667719 on ClinicalTrials.gov